

Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK MIA(IMP) 32954 Insp GMP/IMP 32954/36082496-0002[I]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1),(2)

Part 1

Issued following an inspection in accordance with :

Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

The competent authority of United Kingdom confirms the following :

The Manufacturer : EXMOOR PHARMA CONCEPTS LTD

Site address : EXMOOR PHARMA CONCEPTS LTD, CELL & GENE THERAPY CENTRE, BRITANNIA ROAD, BRISTOL, BS34 5TA, UNITED KINGDOM

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. UK MIA(IMP) 32954 in accordance with Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 12/11/2025 , it is considered that it complies with

- The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

-
- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
 - (2) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Investigational Medicinal Products

1. MANUFACTURING OPERATIONS

[1.1] Sterile Investigational Medicinal Products

[1.1.1] Aseptically prepared (processing operations for the following dosage forms)

[1.1.1.4] Small volume liquids

Special Requirements

Live Cells

[1.1.3] Batch certification

[1.3] Biological investigational medicinal products

[1.3.1] Biological medicinal products

[1.3.1.3] Cell therapy products

Special Requirements

Live Cells

[1.3.1.4] Gene therapy products

Special Requirements

Live Cells

[1.3.1.5] Biotechnology products

[1.3.1.8] Other biological medicinal products

Manufacture of Mammalian Cell Bank

[1.3.2] Batch certification

[1.3.2.3] Cell therapy products

Special Requirements

Live Cells

[1.3.2.4] Gene therapy products

Special Requirements

Live Cells

[1.3.2.5] Biotechnology products

[1.4] Other products or manufacturing activity

[1.4.1] Manufacture of:

[1.4.1.3] Other

Environmental monitoring or process simulation (media fill) to support sterile manufacture

[1.4.2] Sterilisation of active substances/excipients/finished products:

[1.4.2.1] Filtration

[1.5] Packaging

[1.5.1] Primary packaging

[1.5.1.6] Liquids for internal use

[1.5.2] Secondary packaging

[1.6] Quality control testing

[1.6.3] Chemical/Physical

[1.6.4] Biological

18/02/2026 Name and signature of the authorised person of the Competent Authority of United Kingdom

MHRA-GMDP

MHRA

MHRA-GMDP

MHRA